RxDoctor Payments Data

James Kiley, MD

Neurology · Springfield, ORNPI 1861694861

Payments from drug & device makers

$291in general payments, 2019–2025

Across 14 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$84
  • TG Therapeutics, Inc.$59
  • Biogen$28
  • Acorda Therapeutics, Inc$23
  • EMD Serono, Inc.$22
  • Novartis$19
  • plus $57 from 4 others

What the payments were for

  • Speaking & faculty fees$238%
  • Food & beverage$25387%
  • Education$155%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$291 in reported general payments places this provider in the 40th percentile of 228 neurology providers in Oregon.

See all neurology providers in Oregon

Medicare billing

Part B allowed, 2024
$78,417
Medicare patients
311
Services billed
701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a21$172,112
NuplazidPimavanserin Tartrate13$113,514
IngrezzaValbenazine Tosylate12$102,834
Aimovig AutoinjectorErenumab-Aooe108$88,239
BriviactBrivaracetam30$40,292
Lacosamide288$37,819
Glatiramer Acetate24$36,563
AptiomEslicarbazepine Acetate11$28,111
Levetiracetam495$19,205
Carbamazepine ErCarbamazepine103$18,450
UbrelvyUbrogepant17$16,712
Oxtellar XrOxcarbazepine11$13,172
Lamotrigine242$7,675
Gabapentin239$7,592
Memantine Hcl237$7,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$84$40,29230 claims
AbbVieUbrelvy$19$16,71217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 228 neurology providers in Oregon.

Other neurology in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →